RBF Capital’s Fulcrum Therapeutics FULC Stock Holding History

RBF Capital’s Portfolio FULC Stock Details FULC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$256K	Hold	70,000	–	–	0.01%	461
2026 Q1	$537K	Sell	70,000 -10,506	-13%	-$97.5K	0.03%	361
2025 Q4	$911K	Hold	80,506	–	–	0.04%	313
2025 Q3	$741K	Hold	80,506	–	–	0.03%	354
2025 Q2	$554K	Hold	80,506	–	–	0.03%	408
2025 Q1	$232K	Hold	80,506	–	–	0.01%	495
2024 Q4	$378K	Sell	80,506 -25,622	-24%	-$94.5K	0.02%	442
2024 Q3	$379K	Sell	106,128 -18,872	-15%	-$140K	0.02%	465
2024 Q2	$775K	Sell	125,000 -15,000	-11%	-$114K	0.04%	310
2024 Q1	$1.32M	Hold	140,000	–	–	0.07%	252
2023 Q4	$945K	Sell	140,000 -14,100	-9%	-$62.6K	0.06%	285
2023 Q3	$684K	Hold	154,100	–	–	0.05%	306
2023 Q2	$509K	Buy	+154,100	New	+$453K	0.03%	360

Other funds holding FULC

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

RBF Capital's FULC Position: Q2 2026 in Review

RBF Capital held its Fulcrum Therapeutics (FULC) position steady in Q2 2026 at 70,000 shares worth $256K. The position accounts for 0.01% of the portfolio, ranked #461.

RBF Capital first reported a position in FULC in Q2 2023 and has held it in 13 quarters since. The position peaked at $1.32M in Q1 2024. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

RBF Capital held 70,000 shares of Fulcrum Therapeutics worth $256K as of Q2 2026.
RBF Capital left its Fulcrum Therapeutics share count unchanged in Q2 2026.
Fulcrum Therapeutics made up 0.01% of RBF Capital's portfolio in Q2 2026, its #461 holding.
RBF Capital first reported a position in Fulcrum Therapeutics in Q2 2023 and has held it in 13 quarters since.
RBF Capital's Fulcrum Therapeutics position peaked at $1.32M in Q1 2024.
155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on RBF Capital's 13F filing for Q2 2026, filed 14 Aug 2026.